141 related articles for article (PubMed ID: 12168413)
41. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
42. [Treatment strategies for chronic myeloid leukemia].
Jinnai I
Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
[No Abstract] [Full Text] [Related]
43. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
44. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
45. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
46. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
47. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
Kalayoglu-Besisik S; Ozturk GB; Caliskan Y; Nalcaci M; Gurses N; Cin N; Ozbek U; Sargin D
Transfus Apher Sci; 2007 Feb; 36(1):91-4. PubMed ID: 17222585
[TBL] [Abstract][Full Text] [Related]
48. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
[TBL] [Abstract][Full Text] [Related]
49. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
50. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies].
Yagasaki F
Nihon Rinsho; 2007 Jan; 65 Suppl 1():505-10. PubMed ID: 17474456
[No Abstract] [Full Text] [Related]
52. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
[TBL] [Abstract][Full Text] [Related]
53. ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
Ferrario A; Radaelli F; Goldaniga M; F FG; Olivero B; Rossi F; Baldini L
Leuk Res; 2010 Oct; 34(10):e280-1. PubMed ID: 20605208
[No Abstract] [Full Text] [Related]
54. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
Milojkovic D; Short K; Salisbury JR; Creamer D; du Vivier AW; Mufti GJ
Leukemia; 2003 Jul; 17(7):1414-6. PubMed ID: 12835733
[No Abstract] [Full Text] [Related]
55. [Overcoming imatinib resistance].
Ashihara E; Maekawa T
Nihon Rinsho; 2007 Jan; 65 Suppl 1():399-403. PubMed ID: 17474437
[No Abstract] [Full Text] [Related]
56. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.
Lucas CM; Wang L; Austin GM; Knight K; Watmough SJ; Shwe KH; Dasgupta R; Butt NM; Galvani D; Hoyle CF; Seale JR; Clark RE
Leukemia; 2008 Oct; 22(10):1963-6. PubMed ID: 18754023
[No Abstract] [Full Text] [Related]
57. Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
Breccia M; Bocchia M; Cannella L; Defina M; Ippoliti M; Loglisci G; Santopietro M; Lauria F; Alimena G
Br J Haematol; 2010 Jul; 150(2):240-2. PubMed ID: 20346015
[No Abstract] [Full Text] [Related]
58. Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase.
Ng AP; Servadei P; Tuckfield A; Friedhuber A; Grigg A
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):81-3. PubMed ID: 20523168
[TBL] [Abstract][Full Text] [Related]
59. [ATRA (all-trans retinoic acid) in chronic myeloid leukemia?].
Rák K
Orv Hetil; 2002 Jun; 143(23):1449-50; author reply 1450. PubMed ID: 12132331
[No Abstract] [Full Text] [Related]
60. Discontinuation of imatinib may be possible in chronic myelogenous leukemia.
Barton MK
CA Cancer J Clin; 2011; 61(2):65-6. PubMed ID: 21372196
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
